Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: Initial israeli experience

Israel Medical Association Journal

Volumn 6, Issue 2, 2004, Pages 70-74

  Schwammenthal, Yvonne ^a,b   Drescher, Michael J ^a,b   Merzeliak, Oleg ^a,b   Tsabari, Rakefet ^a,b   Bruk, Bella ^a,b   Feibel, Meir ^a,b   Hoffman, Chen ^a,b   Bakon, Mati ^a,b   Rotstein, Zeev ^a,b   Chapman, Joab ^a,b   Tanne, David ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Ischemic stroke; Reperfusion; Thrombolysis; Tissue plasminogen activator; Transcranial Doppler

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN SCINTISCANNING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOPPLER ECHOGRAPHY; DRUG SAFETY; EMERGENCY WARD; FEASIBILITY STUDY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISRAEL; MALE; MAXIMUM PERMISSIBLE DOSE; PHYSICIAN; PRACTICE GUIDELINE; REPERFUSION; SCORING SYSTEM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CEREBROVASCULAR ACCIDENT; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 10744227244     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Causes of Death 1996-1997. Jerusalem: Central Bureau of Statistics, 2000. publication no. 1124.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-8.
3. Broderick JP, Hacke W. Treatment of acute ischemic stroke. Part I: Recanalization strategies. Circulation 2002;106:1563-9.
4. Alberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of primary stroke centers. Brain attack coalition. JAMA 2000;283:3102-9.
5. Demchuk AM, Burgin WS, Christou I, et al. Thrombolysis in Brain Ischemia (TIBI). Transcranial doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001;32:89-93.
6. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: Feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29:18-22.
7. National Institute of Neurological Disease and Stroke. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke. Bethesda, MD: National Institutes of Health; 1997.
8. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study. Neurology 2000;55:1649-55.
9. Alexandrov AV, Burgin WS, Demchuk AM, El-Mitwalli A, Grotta JC. Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: Sonographic classification and short-term improvement. Circulation 2001;103:2897-902.
10. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28:2109-18.
11. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey. Circulation 2002;105:1679-85.
12. Tanne D, Bates VE, Verro P, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey. The t-PA Stroke Survey Group. Neurology 1999;53:424-7.
13. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145-50.
14. Hill MD, Buchan AM. Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators. Can J Neurol Sci 2001;28:232-8.
15. Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001;58:2009-13.
16. Tanne D, Demchuk AM, Kasner SE. Intravenous thrombolysis for acute ischemic stroke: The phase IV data. Semin Cerebrovasc Dis Stroke 2001;1:130-40.
17. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: A Cleveland update. Stroke 2003;34:799-800.
18. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in acute cerebral thromboembolism [see comment]. JAMA 1999;282:2003-11.
19. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: Relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS) cohort. Stroke 1999;30:2280-4.
20. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic tranformation of ischemic brain tissue: Asymptomatic or symptomatic? Stroke 2001;32:1330-5.
21. Tanne D, Gorman MJ, Bates VE, et al. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: The tPA stroke survey experience. Stroke 2000;31:370-5.
22. Tanne D, Turgeman D, Adler Y. Management of acute ischaemic stroke in the elderly: Tolerability of thrombolytics. Drugs 2001;61:1439-53.
23. Koennecke H-C, Nohr R, Leistner S, Marx P. Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience. Stroke 2001;32:1074-8.
24. Morgenstern LB, Staub L, Chan W, et al. Improving delivery of acute stroke therapy: The TLL Temple Foundation Stroke Project. Stroke 2002;33:160-6.
25. Lattimore SU, Chalela J, Davis L, et al. Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: The NINDS Suburban Hospital Stroke Center Experience. Stroke 2003;34:55-7.